FibroGen Net Worth
FibroGen Net Worth Breakdown | FGEN |
FibroGen Net Worth Analysis
FibroGen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including FibroGen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of FibroGen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform FibroGen's net worth analysis. One common approach is to calculate FibroGen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares FibroGen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing FibroGen's net worth. This approach calculates the present value of FibroGen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of FibroGen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate FibroGen's net worth. This involves comparing FibroGen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into FibroGen's net worth relative to its peers.
Enterprise Value |
|
To determine if FibroGen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding FibroGen's net worth research are outlined below:
| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (55.85 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. | |
| FibroGen has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: FibroGen to Report Second Quarter 2025 Financial Results |
FibroGen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in FibroGen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to FibroGen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
FibroGen Target Price Consensus
FibroGen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. FibroGen's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Buy |
Most FibroGen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand FibroGen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of FibroGen, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationFibroGen Target Price Projection
FibroGen's current and average target prices are 6.91 and 10.00, respectively. The current price of FibroGen is the price at which FibroGen is currently trading. On the other hand, FibroGen's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On FibroGen Target Price
Know FibroGen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as FibroGen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading FibroGen backward and forwards among themselves. FibroGen's institutional investor refers to the entity that pools money to purchase FibroGen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2025-03-31 | 404.5 K | State Street Corp | 2025-03-31 | 343.1 K | Ubs Group Ag | 2025-03-31 | 245.6 K | Group One Trading, Lp | 2025-03-31 | 212.1 K | Vantage Consulting Group Inc. | 2025-03-31 | 195.7 K | Northern Trust Corp | 2025-03-31 | 177.9 K | Sei Investments Co | 2025-03-31 | 126.8 K | Ci Private Wealth Llc | 2025-03-31 | 102.1 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 97.7 K | Armistice Capital, Llc | 2025-03-31 | 8.5 M | Vanguard Group Inc | 2025-03-31 | 5.9 M |
Follow FibroGen's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.01 M.Market Cap |
|
Project FibroGen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (1.85) | (1.76) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | 0.26 | 0.25 |
When accessing FibroGen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures FibroGen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of FibroGen's profitability and make more informed investment decisions.
Evaluate FibroGen's management efficiency
FibroGen has return on total asset (ROA) of (0.2273) % which means that it has lost $0.2273 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 6th of August 2025, Return On Tangible Assets is likely to drop to -0.23. In addition to that, Return On Capital Employed is likely to grow to -1.76. As of the 6th of August 2025, Other Current Assets is likely to grow to about 119.6 M, while Total Assets are likely to drop about 203.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.84) | (1.74) | |
| Tangible Book Value Per Share | (1.84) | (1.74) | |
| Enterprise Value Over EBITDA | (0.53) | (0.50) | |
| Price Book Value Ratio | (0.29) | (0.27) | |
| Enterprise Value Multiple | (0.53) | (0.50) | |
| Price Fair Value | (0.29) | (0.27) | |
| Enterprise Value | 164.5 M | 156.2 M |
FibroGen benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 9.6709 | Revenue | Quarterly Revenue Growth (0.89) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific FibroGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on FibroGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases FibroGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
FibroGen Corporate Filings
| 29th of July 2025 Other Reports | ViewVerify | |
8K | 14th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 6th of June 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
FibroGen Earnings Estimation Breakdown
The calculation of FibroGen's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of FibroGen is estimated to be 0.75 with the future projection ranging from a low of 0.75 to a high of 0.75. Please be aware that this consensus of annual earnings estimates for FibroGen is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.75 Lowest | Expected EPS | 0.75 Highest |
FibroGen Earnings Projection Consensus
Suppose the current estimates of FibroGen's value are higher than the current market price of the FibroGen stock. In this case, investors may conclude that FibroGen is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and FibroGen's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2025 | Current EPS (TTM) | |
| 2 | 54.14% | 0.0 | 0.75 | -30.17 |
FibroGen Earnings per Share Projection vs Actual
Actual Earning per Share of FibroGen refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering FibroGen predict the company's earnings will be in the future. The higher the earnings per share of FibroGen, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.FibroGen Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as FibroGen, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of FibroGen should always be considered in relation to other companies to make a more educated investment decision.FibroGen Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact FibroGen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-05-05 | 2025-03-31 | 0.02 | 0.05 | 0.03 | 150 | ||
2025-02-24 | 2024-12-31 | -0.2 | -0.08 | 0.12 | 60 | ||
2024-11-04 | 2024-09-30 | -0.3 | 0.0146 | 0.3146 | 104 | ||
2024-08-06 | 2024-06-30 | -0.32 | -0.16 | 0.16 | 50 | ||
2024-05-06 | 2024-03-31 | -0.42 | -0.33 | 0.09 | 21 | ||
2024-02-26 | 2023-12-31 | -0.42 | -0.57 | -0.15 | 35 | ||
2023-11-06 | 2023-09-30 | -0.68 | -0.52 | 0.16 | 23 | ||
2023-08-07 | 2023-06-30 | -0.7 | -0.9 | -0.2 | 28 | ||
2023-05-08 | 2023-03-31 | -0.75 | -0.81 | -0.06 | 8 | ||
2023-02-27 | 2022-12-31 | -0.94 | -0.7 | 0.24 | 25 | ||
2022-11-07 | 2022-09-30 | -0.81 | -0.98 | -0.17 | 20 | ||
2022-08-08 | 2022-06-30 | -0.94 | -0.78 | 0.16 | 17 | ||
2022-05-09 | 2022-03-31 | -0.83 | -0.68 | 0.15 | 18 | ||
2022-02-28 | 2021-12-31 | -0.66 | -1.45 | -0.79 | 119 | ||
2021-11-09 | 2021-09-30 | -0.01 | 0.54 | 0.55 | 5500 | ||
2021-08-09 | 2021-06-30 | -0.48 | -1.45 | -0.97 | 202 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 | ||
2021-03-01 | 2020-12-31 | -0.24 | -0.64 | -0.4 | 166 | ||
2020-11-05 | 2020-09-30 | -0.8 | 0.35 | 1.15 | 143 | ||
2020-08-06 | 2020-06-30 | -0.64 | -0.95 | -0.31 | 48 | ||
2020-05-07 | 2020-03-31 | -0.39 | -0.89 | -0.5 | 128 | ||
2020-03-02 | 2019-12-31 | -0.59 | -1.12 | -0.53 | 89 | ||
2019-11-11 | 2019-09-30 | -0.55 | -0.57 | -0.02 | 3 | ||
2019-08-08 | 2019-06-30 | -0.51 | 1.26 | 1.77 | 347 | ||
2019-05-09 | 2019-03-31 | -0.67 | -0.53 | 0.14 | 20 | ||
2019-02-27 | 2018-12-31 | -0.1 | 0.25 | 0.35 | 350 | ||
2018-11-08 | 2018-09-30 | -0.35 | -0.5 | -0.15 | 42 | ||
2018-08-07 | 2018-06-30 | -0.59 | -0.28 | 0.31 | 52 | ||
2018-05-09 | 2018-03-31 | -0.51 | -0.5 | 0.01 | 1 | ||
2018-02-27 | 2017-12-31 | -0.28 | -0.27 | 0.01 | 3 | ||
2017-11-08 | 2017-09-30 | -0.37 | -0.5 | -0.13 | 35 | ||
2017-08-07 | 2017-06-30 | -0.47 | -0.48 | -0.01 | 2 | ||
2017-05-09 | 2017-03-31 | -0.49 | -0.52 | -0.03 | 6 | ||
2017-03-01 | 2016-12-31 | -0.53 | -0.54 | -0.01 | 1 | ||
2016-11-08 | 2016-09-30 | -0.6 | -0.38 | 0.22 | 36 | ||
2016-08-08 | 2016-06-30 | 0.36 | 0.35 | -0.01 | 2 | ||
2016-05-09 | 2016-03-31 | -0.56 | -0.45 | 0.11 | 19 | ||
2016-02-29 | 2015-12-31 | -0.41 | -0.85 | -0.44 | 107 | ||
2015-11-12 | 2015-09-30 | -0.59 | -0.74 | -0.15 | 25 | ||
2015-08-13 | 2015-06-30 | 0.73 | 0.83 | 0.1 | 13 | ||
2015-05-12 | 2015-03-31 | -0.52 | -0.78 | -0.26 | 50 | ||
2015-03-26 | 2014-12-31 | -0.9 | -0.82 | 0.08 | 8 |
FibroGen Corporate Management
| Kirk MBA | Chief Officer | Profile | |
| Rahul Kaushik | Technical Development | Profile | |
| Mr JD | Chief Officer | Profile | |
| Enrique Conterno | CEO Director | Profile | |
| Barry Berkowitz | Founder | Profile | |
| Christine Chung | Senior Operations | Profile | |
| David DeLucia | Vice Relations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (30.17) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.